Often, yes. In non-small cell lung cancer, changes in genes like EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET, RET, HER2 and NTRK each have at least one targeted drug, and many of them are pills you take at home. Whether a drug fits you depends on the exact change on your report, the stage of your cancer and what treatment you have already had, so your oncologist matches the result to the drug.
Just got your biomarker results?
Hope AI by Manta Cares can help you understand what each line of your report means and work out what to ask your oncologist about it. It is built on clinically reviewed cancer content, not general web search, so the answers fit what you are actually going through. Free for patients and care partners.
Ask Hope AI about your resultsWhat is a targeted therapy?
A targeted therapy is a drug built to block one specific change that helps a cancer grow. Chemotherapy attacks cells that divide quickly, whether they are cancer cells or not. A targeted drug goes after the change itself, so it only works if your cancer has that change.
Many non-small cell lung cancers are driven by one main gene change, and many of those changes have a matching targeted drug. That is why biomarker testing comes first. The test looks for gene changes in your tumor, and the result tells your team whether a targeted drug is an option. Some of these changes are called mutations, and some are called rearrangements or fusions, which means part of one gene has broken off and joined another.
Which lung cancer mutations have a targeted drug?
These are the gene changes with targeted drugs approved in the US for non-small cell lung cancer. The drug names are examples, not a full list, and your oncologist picks the right one for you.
EGFR
The most common changes are in parts of the gene called exon 19 and exon 21. Drugs include osimertinib, erlotinib, gefitinib, and afatinib, which are pills, and amivantamab, which is given by IV or injection and is sometimes combined with a pill called lazertinib or with chemo. A less common change called an exon 20 insertion is treated differently, with amivantamab or a pill called sunvozertinib.
ALK
ALK changes are rearrangements. Drugs include alectinib, lorlatinib, brigatinib, ensartinib, crizotinib, and neladalkib, all taken by mouth.
ROS1
ROS1 changes are also rearrangements. Drugs include entrectinib, crizotinib, repotrectinib, taletrectinib, lorlatinib, and zidesamtinib, taken by mouth.
KRAS G12C
KRAS has many possible changes, and only one of them, G12C, has approved targeted pills: sotorasib and adagrasib. If your report shows a different KRAS change, ask your oncologist whether a clinical trial fits.
BRAF V600E
This change is usually treated with two pills together, dabrafenib with trametinib or encorafenib with binimetinib.
MET
A change called MET exon 14 skipping is treated with the pills capmatinib or tepotinib. Some cancers make too much MET protein instead, and a drug given by IV called telisotuzumab vedotin may be an option after other treatment.
RET
RET changes are rearrangements. Drugs include selpercatinib and pralsetinib, taken by mouth.
HER2
HER2 mutations can be treated with two newer pills, zongertinib and sevabertinib, which in 2026 became options as a first treatment. An IV drug called fam-trastuzumab deruxtecan is used after other treatment.
NTRK and NRG1
These are rare fusions. NTRK fusions can be treated with larotrectinib, entrectinib or repotrectinib. NRG1 fusions can be treated with an IV drug called zenocutuzumab after other treatment.
What if my report shows a mutation with no matching drug?
Many reports list several gene changes, and not all of them have a drug. Some changes, like many in a gene called TP53, are common in lung cancer but do not have a targeted drug. Others are listed as a "variant of unknown significance," which means scientists do not yet know whether the change matters.
A change with no matching drug does not mean you have no treatment. Your team will usually look at chemotherapy, immunotherapy or both, and may suggest a clinical trial. Ask which changes on your report your oncologist is acting on, and which ones they are setting aside and why.
If you are holding your report right now, where do you start?
Look for the section with a heading like "results," "genomic findings" or "biomarkers." Each line usually shows a gene name, then the exact change, such as "EGFR exon 19 deletion" or "KRAS G12C."
Some reports also sort findings by how strong the evidence is for a drug, or list FDA-approved drugs next to a result. Those notes are a starting point for the conversation, not a treatment plan. Write down the exact gene and change for each line, because the specific change, not just the gene name, decides which drug fits.
Your report may also say whether the test used tumor tissue or blood. A blood test, called a liquid biopsy, looks for bits of tumor DNA in your blood. It can find many of the same changes, but it can miss them, so a blood test that finds nothing does not always mean nothing is there. Ask whether a tissue test is also planned.
Results, drug names and questions, all in one place
Biomarker results bring a lot of new words at once: gene names, drug names, test names and dates. The free Manta Cares platform keeps your appointments, medications, symptoms and questions in one place, so what you need is already there when you sit down with your oncologist. Free for patients and care partners.
Start organizing your care with Manta CaresWill I take a targeted drug instead of chemo or immunotherapy?
For advanced lung cancer with a matching change, a targeted drug is often the first treatment your oncologist recommends. The targeted therapy may be combined with chemo, or even with another targeted drug; combination therapy is common for treatments directed against changes in EGFR. If your cancer has no matching change, chemo, immunotherapy or both are more common first choices.
Targeted drugs are also used for some earlier-stage cancers. After surgery, osimertinib can be used for some EGFR-positive cancers, and alectinib for some ALK-positive cancers, to lower the chance the cancer comes back.
What side effects should I expect?
Side effects depend on the drug class. Some common ones:
- EGFR drugs: Rash and other skin problems, nail changes, diarrhea, tiredness and loss of appetite
- ALK and ROS1 drugs: Vision changes, swelling, nausea, diarrhea, tiredness and nerve tingling
- KRAS G12C drugs: Diarrhea, nausea, muscle pain and tiredness
- BRAF drugs: Fever, rash, sun sensitivity, headache and nausea
- RET and MET drugs: Swelling, high blood pressure, diarrhea or constipation, and tiredness
A few side effects need a call right away. Lung inflammation, called pneumonitis, can show up as a new cough or shortness of breath. Some drugs can also affect the liver, kidneys or heart rhythm, or cause blood clots. Ask your team which symptoms they want to hear about the same day.
How will I know if it is working?
Your team will check with scans, usually every few months, and will ask how you feel. Some people notice their breathing or cough get better within weeks. Others feel no change, and the scan is how you find out. Ask when your first scan will be and what result would change the plan.
What happens if the targeted drug stops working?
Over time, many cancers find a way around a targeted drug. This is called resistance. The cancer may develop a new gene change that stops the drug from attaching, or it may start using a different growth signal.
When that happens, your team often orders another biomarker test, from a new biopsy, a blood test or both, to see what changed. The result can point to a different targeted drug, chemo, another treatment or a clinical trial. Resistance does not mean you have run out of options.
What should I ask my oncologist?
You do not need to ask every question. Pick the ones that matter most to you.
- Which gene changes did my test find, and which one are you treating?
- Was the test done on tissue, blood or both? Is any more testing needed?
- Is there an approved targeted drug for my change? Why this one?
- Is it a pill or an IV, and how often will I take it?
- Which side effects should I call about right away?
- When is my first scan, and how will we know it is working?
- If it stops working, what would we test for next?
- Is there a clinical trial that fits my result?
Also Read:
- What is biomarker testing, and why is it important for lung cancer patients?
- Chemotherapy vs immunotherapy for lung cancer
- I just got a cancer diagnosis. What happens next?
Frequently asked questions
Q: What does it mean that my lung cancer is EGFR positive?
Ans - It means your tumor has a change in the EGFR gene that helps the cancer grow. Several targeted drugs block EGFR, and for advanced cancer one of them is often the first treatment. Your oncologist chooses the drug based on the exact change.
Q: Is targeted therapy a pill?
Ans - Many targeted drugs for lung cancer are pills you take at home, often once or twice a day. Some, like amivantamab and fam-trastuzumab deruxtecan, are given by injection at a treatment center.
Q: Does every lung cancer mutation have a targeted drug?
Ans - No. Changes in EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET, RET, HER2, NTRK and NRG1 have approved drugs, but many other changes do not. If yours does not, your team will look at chemotherapy, immunotherapy or a clinical trial.
Q: Can a blood test find my mutation?
Ans - Often, yes. A liquid biopsy looks for tumor DNA in the blood and can find many of the same changes as a tissue test. It can also miss them, so a blood test that finds nothing does not always rule out a change.
Q: What happens when targeted therapy stops working?
Ans - Your team usually tests again, from a new biopsy, a blood test or both, to see how the cancer changed. The result can point to a different targeted drug, chemo, another treatment or a clinical trial.
Trying to make sense of your biomarker report?
Hope AI by Manta Cares is not a general chatbot searching the web. It is built on clinically reviewed cancer content and connected to the rest of the platform, so it can show you where you are on your Cancer Map and point you toward the decision support and organizational tools that fit your situation. Available whenever you need it, free for patients and care partners.
Sign in to chat with Hope AI